Vasculox, St. Louis, MO, is a biotech company focused on the development of proprietary drugs for life-threatening disorders driven by CD47-mediated signaling pathways such as leukemia, lymphoma, solid tumors, pulmonary hypertension and delayed graft function following solid organ transplantation.
|